David Meeker Rhythm Pharmaceuticals (NASDAQ:RYTM) appointed its chairman, Dr. David Meeker as CEO, effective immediately. Dr. Meeker replaces interim president and CEO, Hunter Smith, who will continue in his role as CFO...
Rhythm Pharmaceuticals (NASDAQ:RYTM) completed enrollment of the pivotal cohort in its Phase 3 trial of setmelanotide for the treatment of insatiable hunger and severe obesity in Bardet-Biedl syndrome (BBS) or Alström...